Wilson's Disease Clinical Trial
Official title:
DEEP BRAIN STIMULATION FOR SEVERE DYSTONIA ASSOCIATED WITH WILSON'S DISEASE. A Prospective Multicenter Meta-analysis of Nof1 Trials
Dystonia in Wilson's disease represent a major issue. The persistence of disabling motor symptoms despite medical treatments justifies conducting a study on deep brain stimulation (DBS) in Wilson's disease (WD). For bradykinetic patients, subthalamic nucleus (STN) could be considered as a better target than the globus pallidus (GPi). For patients with hyperkinetic dystonia, the internal globus pallidus (GPi) will be chosen as the target of DBS. The investigators hypothesize that STN DBS will improve Wilson's disease patients, who, despite copper chelators drugs, are still impaired by severe dystonia and akinesia (more or less associated with other movement disorders). The investigators primary objective is to demonstrate the efficacy of STN/GPi DBS on dystonia associated with Wilson's disease. Secondary objectives: - To evaluate the impact of STN/GPi DBS on other movements disorders (tremor, Parkinsonism, chorea) observed in Wilson's disease. - To describe cognitive status of patients and to evaluate the consequences of STN/GPi DBS on cognition and behavioral aspects of the disease. - To evaluate the consequences of the stimulation on speech and swallowing. - To evaluate the social impact of STN/GPi DBS in Wilson's disease. - To evaluate the safety of STN/GPi DBS in the specific context of Wilson's disease.
4 periods of stimulation on and off, sequence randomized at Day 0. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04537377 -
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06051734 -
Early Detection of Cardiac Affection in Patients of Wilson's Disease
|
||
| Active, not recruiting |
NCT02252380 -
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
|
N/A | |
| Completed |
NCT01874028 -
A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients
|
Phase 1 | |
| Recruiting |
NCT05183165 -
Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease
|
N/A | |
| Completed |
NCT00212355 -
Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.
|
Phase 3 | |
| Recruiting |
NCT05493605 -
Cardiac Involvement in Wilson's Disease
|
N/A | |
| Recruiting |
NCT03957720 -
The Individual Therapy for Patients With Wilson's Disease
|
Early Phase 1 | |
| Recruiting |
NCT05239858 -
International Wilson's Disease Patient Registry (iWilson Registry)
|
||
| Recruiting |
NCT04012658 -
A Registered Cohort Study on Wilson's Disease
|
||
| Completed |
NCT06128954 -
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
|
Phase 1 | |
| Recruiting |
NCT05305872 -
Gandouling in the Treatment of Wilson's Disease
|
Phase 4 | |
| Recruiting |
NCT04212195 -
Cohort Research on Wilson's Disease
|
||
| Completed |
NCT01378182 -
Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis
|
N/A |